Category: us corporate news

us corporate news

Gulfport Energy Announces CEO Departure and Interim Leadership Team Formation in 2026

Minichart

March 9, 2026

Gulfport Energy Announces Leadership Transition and Maintain...

Continue Reading 0

us corporate news

Fluor Corporation SEC 8-K Filing March 3, 2026: Company Details, Address, and XBRL Data Summary

Minichart

March 9, 2026

Fluor Corporation Announces Board Changes and Director Appoi...

Continue Reading 0

us corporate news

Cartesian Therapeutics Reports 2025 Financial Results, Advances Descartes-08 Cell Therapy in Autoimmune Diseases and Myasthenia Gravis Phase 3 Trial

Minichart

March 9, 2026

Cartesian Therapeutics Reports Full Year 2025 Financial Resu...

Continue Reading 0

us corporate news

enGene Reports Q1 2026 Results, Advances Detalimogene for Bladder Cancer with Strong Cash Position and FDA Milestones 12

Minichart

March 9, 2026

enGene Holdings Inc. Reports First Quarter 2026 Financial Re...

Continue Reading 0

us corporate news

iBio Reports Promising Preclinical Results for IBIO-610 Activin E Antibody in Fat-Selective Weight Loss for Obesity and Cardiometabolic Diseases 1

Minichart

March 9, 2026

iBio, Inc. Announces Promising Preclinical Results for IBIO-...

Continue Reading 0

us corporate news

Boundless Bio Reports Q4 and Full Year 2025 Financial Results, Highlights Progress of KOMODO-1 Clinical Trial and BBI-940 Program

Minichart

March 9, 2026

Boundless Bio Reports Q4 and FY2025 Results and Clinical Upd...

Continue Reading 0

us corporate news

Duke Energy Announces $1 Billion Convertible Senior Notes Offering to Refinance 2026 Debt

Minichart

March 9, 2026

Duke Energy Announces Proposed \$1 Billion Convertible Senio...

Continue Reading 0

us corporate news

enCore Energy Reports 2025 Year-End Results: Strong Uranium Production, Improved Financials, and U.S. Project Advancements

Minichart

March 9, 2026

enCore Energy Corp. Reports 2025 Year-End Financials and Pro...

Continue Reading 0

us corporate news

Relmada Therapeutics Announces 76% 12-Month Complete Response Rate in Phase 2 NDV-01 Trial for High-Risk Non-Muscle Invasive Bladder Cancer

Minichart

March 9, 2026

Relmada Therapeutics Reports Promising 12-Month Phase 2 Data...

Continue Reading 0

us corporate news

3D Systems Corporation Reports 2025 Financial Results: Revenue, Gross Profit, and Segment Performance Analysis

Minichart

March 9, 2026

3D Systems Corporation Reports Q4 and Full Year 2025 Financi...

Continue Reading 0